Raludotatug deruxtecan - Daiichi Sankyo
Alternative Names: DS-6000; DS-6000a; MK-5909; R-DXdLatest Information Update: 05 Apr 2024
At a glance
- Originator Daiichi Sankyo Company
- Developer Daiichi Sankyo Company; Merck & Co
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Phase I Renal cell carcinoma
Most Recent Events
- 27 Feb 2024 Phase-II/III clinical trials in Fallopian tube cancer (Second-line therapy or greater) in Japan (IV) (NCT06161025)
- 27 Feb 2024 Phase-II/III clinical trials in Ovarian cancer (Second-line therapy or greater) in Japan (IV) (NCT06161025)
- 27 Feb 2024 Phase-II/III clinical trials in Peritoneal cancer (Second-line therapy or greater) in Japan (IV) (NCT06161025)